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Synthesis, lipid modification and proteolytic processing of the major lipoprotein from Escherichiu coli is shown to occur 
in a homologous in vitro transcription-translation system containing inverted plasma membrane vesicles. The primary 
translation product (cross-reacting with anti-lipoprotein antiserum) is a precursor which is converted into a lower molecu- 
lar mass species of the size of mature lipoprotein by the addition of inverted membrane vesicles from E. coli. Conversion 
is prevented by globomycin, a specific inhibitor of the unique lipoprotein-signal peptidase II, which is active only on 
lipid-containing precursors. The inverted plasma membrane vesicles used here must therefore contain active lipid-modify- 
ing enzymes and signal peptidase II. 
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1, INTRODUCTION 
The synthesis of Braun’s lipoprotein encom- 
passes a series of distinct steps (recently reviewed 
in [l]): (i) it is initially synthesized as a lipid-free, 
signal sequence-containing precursor (frequently 
termed prolipoprotein); (ii) glycerol is then trans- 
ferred from phosphatidyl glycerol to the Cys 
located at the SPase-cleavage site; (iii) glycerol is 
subsequently esterified with fatty acids; (iv) the di- 
glyceride-prolipoprotein is the immediate substrate 
for SPase II [2] which differs from SPase I by its 
requirement for a lipid modification of the sub- 
strate as well as by its inhibition by globomycin; (v) 
after removal of the signal peptide, the a-NH2 
group of the lipid-modified Cys is acylated to give 
the mature lipoprotein, These processing events 
occur within the plasma membrane. 
To study the mechanism of protein translocation 
across the bacterial plasma membrane, in vitro 
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systems have recently been developed as useful ex- 
perimental tools [3,4]. Several precursors to ex- 
ported proteins were thus synthesized in a cell-free 
system and found to be translocated into INVs. 
Here we demonstrate for the first time that the 
complex processing of Braun’s lipoprotein can also 
be reproduced in such a cell-free system. 
2. MATERIALS AND METHODS 
Proteins were synthesized in the cell-free system prepared as 
described [4] from E. coli K12 strain MC4100 [5]. The system 
was programmed with plasmid pKEN125 [6] DNA and, other 
than in [4], supplemented with 0.5 mM each of CTP and UTP 
to allow for simultaneous transcription-translation. Reactions 
were stopped with 5% trichloroacetic acid. INVs were prepared 
as described [4]. Globomycin was kept as 10 mg/ml stock solu- 
tion in methanol and added to a final concentration of 
10 fig/ml. 
3. RESULTS AND DISCUSSION 
In order to study the biosynthesis of lipoprotein 
in yitro, an experimental system was required that 
wobld allow resolution of the lipid-free and lipid- 
containing precursors, and of the lipid-modified; 
proteolyticahy processed (mature) lipoprotein, As 
shown in fig. 1, all three lipoprotein species which 
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can be obtained by immunoprecipitation from E. 
coli strain MM18, are in fact resolved by SDS- 
urea-PAGE. 
The characteristic feature of MM18 cells is the 
maltose-inducible synthesis of a hybrid protein be- 
tween the periplasmic maltose-binding protein and 
the cytoplasmic ,&galactosidase which is 
presumably too bulky to be completely trans- 
located [7], thereby interfering with normal pro- 
tein export. When MM18 cells are grown in the 
absence of maltose, however, they export proteins 
at wild type level. Accordingly, the major [‘%I- 
methionine-labeled, lipoprotein-cross-reacting an- 
tigen of MM18 cells grown without maltose 
migrates in SDS-urea-PAGE with an apparent 
molecular mass of 6 kDa which due to its size and 
immunogenicity is the mature lipoprotein (lane 3, 
arrow). (Additional immunoreactive proteins 
recognized by the antiserum are probably other 
envelope proteins, since the lipoprotein used for 
immunization had not been homogeneously 
purified.) 
When globomycin is added to the MM18 culture 
prior to the radioactive methionine, a 7.5 kDa pro- 
tein (lane 2, open arrowhead) is immuno- 
precipitated in addition to the 6 kDa form. Since 
globomycin specifically inhibits SPase II, an en- 
zyme which requires a lipid modification of its sub- 
strate, the 7.5 kDa lipoprotein-must be uncleaved 
and lipid-modified [8]. 
If however, MM18 cells are grown in the 
presence of maltose, the maltose-induced over- 
production of the hybrid protein leads to a jamm- 
ing of the plasma membrane and, thereby, causes 
the accumulation of a variety of precursors to ex- 
ported proteins, including prolipoprotein [9]. As 
shown on lane 1 (closed arrowhead), the major 
lipoprotein species, immunoprecipitated from 
maltose-induced MM18 cells appear to be smaller 
(7 kDa) on the SDS-urea-gel than the globomycin- 
arrested precursor (lane 2, open arrowhead). This 
is consistent with its being the lipid-free prolipo- 
protein [lo] accumulating, because the abundant 
deposition of the maltose-induced hybrid protein 
at the plasma membrane supposedly blocks the ac- 
cess to the membrane-located, modifying enzymes 
and SPase II. 
:: Fig.2 compares the three in vivo labeled, im- 
munoreactive lipoprotein forms to various species 
synthesized in vitro. A cell-free transcription- 
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Fig. 1. Biosynthetic intermediates of lipoprotein accumulate in 
MM18 cells grown under various conditions. Cells of strain 
MM18 [5] were grown at 30°C in M63 medium [lo] containing 
0.4% glycerol up to an Asee = 0.6, whereupon three portions of 
3 ml each were incubated for additional 120 min at 30°C. The 
first culture obtained 0.4% maltose at t = 0 (lane l), the second 
globomycin at t = 110 min (lane 2), the third culture served as 
control (lane 3). Cells were labeled with [35S]methionine 
(30 &i/ml) for 2 min and lipoprotein was immunoprecipitated 
as described [5]. Proteins were separated on 22% PAGE in the 
presence of SDS and urea [ 121 and visualized by fluorography. 
Arrow, mature lipoprotein; open arrowhead, lipid-containing 
precursor; closed arrowhead, lipid-free precursor. Numbers to 
the left indicate molecular mass of r4C-methylated marker pro- 
teins. 
translation system prepared from E. coli showed 
little protein synthesis (lane 2), unless programmed 
with plasmid pKEN125 containing the lipoprotein 
gene. Plasmid pKEN125 leads to the specific syn- 
thesis of a heavily expressed 7 kDa protein (cf. 
lanes 2 and 3) which is recognized by the anti-lipo- 
protein antiserum (lane 4) and co-migrates with the 
lipid-free lipoprotein precursor immuno- 
precipitated from maltose-induced MM18 cells 
(lane 1, arrowhead). The 7 kDa translation 
product therefore is the non-processed precursor 
of Braun’s lipoprotein. 
As previously found for precursors to various 
export proteins [3,4] in vitro processing requires 
the presence of INVs. As shown in fig.2, lanes 5 
and 6, addition of INVs gives rise to a lipoprotein 
cross-reacting form of 6 kDa. This 6 kDa material 
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Fig.2. In vitro synthesis and globomycin-sensitive processing of 
lipoprotein by inverted plasma membrane vesicles. “S-labeled 
proteins obtained by cell-free transcription-translation of 
pKEN125 DNA are displayed as described in fig.1. For direct 
comparison, samples identical to those shown in fig.1, lanes l-3 
(however after a shorter exposure) were included in this experi- 
ment, lanes 1, 9, 7. Arrows and numbers on the left are as in 
fig.1. 
is resolved into 2-3 subspecies on SDS-urea- 
PAGE, one of them co-migrating exactly with the 
mature lipoprotein immunoprecipitated from 
MM18 cells (arrows, lanes 5 and 7). That these 
6 kDa peptides, appearing only in the pres&ce of 
INVs, indeed represent lipid-modified and pro- 
teolytically processed lipoprotein is clearly 
demonstrated by the finding that their appearance 
is completely abolished by including globomycin in 
the translation mixture (cf. lanes 5 and 8). Since 
globomycin is a specific inhibitor of SPase II, 
failure of INVs to conduct proteolytic conversion 
in the presence of globomycin is the strongest in- 
dication we have for the 6 kDa peptides being the 
cleavage products of the INV-located SPase II. 
Moreover, since the prerequisite for precursors be- 
ing cleaved by this peptidase is the attachment of 
a diglyceride, the lipoprotein which accumulates as 
a result of SPase II inhibition (lane 8), must have 
undergone lipid modification. This is fully consis- 
tent with (i) its electrophoretic co-migration with 
the lipid-containing prolipoprotein accumulating 
in globomycin-treated MM18 cells (lane 9, arrow- 
head), and (ii) its higher apparent molecular mass 
when compared to the major part of the lipid-free 
The reason for the heterogeneity of the 6 kDa 
lipoprotein species (and also for that of the non- 
cleaved precursor) remains obscure. The calculated 
difference in molecular mass between the single 
bands amounts to approx. 2-3 kDa. This could 
conceivably reflect a mixed population of mono- 
and diglycendes or also different fatty acids at- 
tached via the glycerol [ 111, Alternatively, splitting 
of the bands on SDS-urea-PAGE could merely be 
caused by a differential association of lipoprotein 
molecules with various amounts of SDS. 
In summary, we have presented evidence for the 
capability of INVs to conduct lipid modification 
and the lipoprotein-specific removal of the signal 
peptide. The vesicles must therefore contain, in ad- 
dition to SPase I [4]: active lipoprotein-specific 
SPase II, glyceryl transferase, as well as acyl trans- 
ferases. These findings emphasize the authenticity 
of bacterial protein export events conducted by 
INVs. 
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